Go to deals
Healthcare

Procaps S.A. has completed a private placement of senior notes

Procaps S.A. has raised funds to refinance existing debt with new institutional investors.

Procaps is a leading integrated international healthcare and pharmaceutical company that develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high-potency clinical solutions. Procaps has a product reach in 50 markets and has strategically positioned itself to achieve its M&A initiative and expand new product categories in the B2B and B2C segments.

Oaklins’ team in Chile acted as the sole financial advisor to Procaps S.A. in the private placement of senior unsecured fixed-rate notes for an aggregate principal amount of US$115 million.

Talk to the deal team

Sebastián Cereceda

Partner
Santiago, Chile
Oaklins LarrainVial

Valentina Rodríguez

Analyst
Santiago, Chile
Oaklins LarrainVial

Related deals

Rare Patient Voice has been acquired by Konovo
Healthcare | TMT

Rare Patient Voice has been acquired by Konovo

Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.

Learn more
GSP Group has secured an upsized growth refinancing package from HSBC
Business Support Services | Construction & Engineering Services

GSP Group has secured an upsized growth refinancing package from HSBC

The GSP Group has refinanced its growth facilities through an upsized financing package provided by HSBC.

Learn more
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more